Vertex to Participate in Upcoming November Investor Conferences

VRTX 10.29.2024

Full Press ReleaseSEC FilingsOur VRTX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
  • 01.12.2025 - Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities

BOSTON--(BUSINESS WIRE)--Oct. 29, 2024--Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.

  • Dr.Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at theGuggenheim Inaugural Healthcare Innovation ConferenceonTuesday, November 12, 2024at9:00 a.m. ET.
  • Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat at theStifel Healthcare ConferenceonTuesday, November 19, 2024at8:00 a.m. ET.

A live webcast of management's remarks will be available through theVertexwebsite,www.vrtx.comin the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

AboutVertexVertexis a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases.Vertexalso has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertexwas founded in 1989 and has its global headquarters inBoston, with international headquarters inLondon. Additionally, the company has research and development sites and commercial offices inNorth America,Europe,Australia,Latin Americaand theMiddle East.Vertexis consistently recognized as one of the industry's top places to work, including 15 consecutive years onScience magazine'sTop Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more aboutVertex's history of innovation, visitwww.vrtx.comor follow us onLinkedIn,Facebook,Instagram,YouTubeandX.

(VRTX-WEB)

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241029053925/en/

Vertex Pharmaceuticals IncorporatedInvestors:InvestorInfo@vrtx.com

Source:Vertex Pharmaceuticals Incorporated

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com